Scott Segel
Endocrinology, Diabetes & Metabolism · Williamsport, PANPI 1063416535
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $126,855 of the $136,764 with a category attached, or 92.8%. Novo Nordisk accounts for 87.3% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $51,221 and has fallen 73.6% since, to $13,524 in 2025. Among endocrinology, diabetes & metabolism clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 207 payments — averaging $660.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$119K
- AstraZeneca$15K
- Boehringer Ingelheim$275
- Abbott$223
- Sanofi-aventis U.S. LLC$184
- Tandem Diabetes Care, Inc.$165
- plus $1K from 12 others
Across 45 payments — averaging $7490.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$296K
- Pfizer$32K
- Boehringer Ingelheim International GmbH$10K
What the payments were for
- Speaking & faculty fees$126,85593%
- Travel & lodging$4,5673%
- Food & beverage$5,1334%
- Education$2090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 134 | $119,446 |
| AstraZeneca | 28 | $15,339 |
| Boehringer Ingelheim | 2 | $275 |
| Abbott | 7 | $223 |
| Sanofi-aventis U.S. LLC | 3 | $184 |
| Tandem Diabetes Care, Inc. | 4 | $165 |
| Medtronic | 3 | $154 |
| Sequel Med Tech, LLC | 1 | $145 |
| Dexcom, Inc. | 3 | $126 |
| Insulet Corporation | 7 | $123 |
| AbbVie | 2 | $120 |
| Ascendis Pharma Endocrinology Inc | 1 | $106 |
| Radius Health, Inc. | 2 | $98 |
| Amgen | 4 | $97 |
| Lilly USA, LLC | 3 | $90 |
| Rhythm Pharmaceuticals, Inc. | 1 | $33 |
| Merck | 1 | $28 |
| Senseonics, Incorporated | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$65,488
- RYBELSUS$33,009
- FARXIGA$14,875
- Tresiba$10,540
- Xultophy 100/3.6$5,368
- JARDIANCE$275
- TWIIST$145
- TZIELD$123
- Synthroid$108
- FreeStyle Libre Pro$102
How this compares
$136,764 in reported general payments places this provider in the 90th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 396 | $534,763 |
| JardianceEmpagliflozin | 194 | $235,301 |
| MounjaroTirzepatide | 88 | $106,168 |
| TrulicityDulaglutide | 77 | $105,295 |
| FarxigaDapagliflozin Propanediol | 59 | $76,674 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $68,334 |
| Novolog FlexpenInsulin Aspart | 147 | $39,352 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 47 | $32,862 |
| Tresiba Flextouch U-100Insulin Degludec | 42 | $30,314 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 194 | $29,461 |
| TradjentaLinagliptin | 25 | $26,067 |
| SynthroidLevothyroxine Sodium | 266 | $21,089 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $19,838 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 23 | $19,332 |
| InvokanaCanagliflozin | 19 | $19,062 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $119,446 | $567,125460 claims |
| Boehringer IngelheimJardiance, Tradjenta | $275 | $261,368219 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $90 | $222,191193 claims |
| AstraZenecaFarxiga | $15,339 | $76,67459 claims |
| AbbVieSynthroid | $120 | $21,089266 claims |
| MerckJanuvia | $28 | $13,28012 claims |
| Sanofi-aventis U.S. LLCLantus | $184 | $4,87831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Williamsport
- Serge JabbourPhiladelphia$1.2M
- Vijay BahlPittsburgh$998K
- Geraldo SaavedraWhitehall$698K
- Jane MayrinPhiladelphia$628K
- Stephan KowalykGreensburg$591K
- Matthew KaneWest Chester$577K
- Intekhab AhmedPhiladelphia$528K
- Swarna VarmaPittsburgh$520K
- James DickeHanover$425K
- Mitchell LazarPhiladelphia$358K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.